Stage i NSCLC: Elucidating the prognostic factors

Thorax

Volumn 64, Issue 3, 2009, Pages 185-186

  Pham, Duykhanh ^a   Harpole, David H ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CADHERIN; CARCINOEMBRYONIC ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; H CADHERIN; KI 67 ANTIGEN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UNCLASSIFIED DRUG; VASCULOTROPIN;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; DNA MICROARRAY; EDITORIAL; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; TUMOR VOLUME;

EID: 61649121742     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2008.105965     Document Type: Editorial

References (18)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Harpole DH Jr, Herndon JE, Young WG, et al. Stage I non-small cell lung cancer. Cancer 1995;76:787-96.
3. IALT Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
4. Winton T, Livington R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resetced non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
5. Strauss GM, Merndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51.
6. Douillard JY, Rossell R, De Lena M, et al. Adjuvant vlnorelblne plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27.
7. Hung J-J, Hsu W-H, Hsleh C-C, et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 2009;64:192-6.
8. Brock MV, Hooker CM, Ota-Machlda E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008 13;358:1118-28.
9. Ohta T, Tanaka Y, Watannabe G, et al. Predicting recurrence following curative surgery in stage I non-small cell lung cancer patients using an anglogenesis-assoclated factor. J Exp Clin Cancer Res 2007;26:301-5.
10. Yilmaz A, Ernam D, Unsal E, et al. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer. Arch Med Res 2007;38:764-8.
11. Matsuoka K, Sumitomo S, Nakashlma N, et al. Prognostic value of carcinoembryonic antigen and CYFRA21-1 In patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2007;32:435-9.
12. Inoue M, Takakuwa T, Minami M, et al. Clinlcopathologlc factors influencing postoperative prognosis in patients with small-sized adenocarcinoma of the lung. J Thorac Cardiovasc Surg 2008;135:830- 6.
13. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence In pathologic stage I NSCLC patients. Cancer 2006;107:2866-72.
14. Jiang F, Yin Z, Caraway NP, et al. Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays. Neoplasia 2004;6:623-35.
15. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80.
16. Larsen JE, Pavey SJ, Passmore LH, et al. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 2007;13:2956-64.
17. Harpole DH. Prognostic modeling in early stage lung cancer: an evolving process from histopathology to genomics. Thor Surg Clin 2007;17:167-73, vii.
18. Anguiano A, Nevins JR, Potti A. Toward the individualization of lung cancer therapy. Cancer 2008;113(7 Suppl):1760-7.